Keytruda meets in first-line NSCLC with low PD-L1 expression
Merck & Co. Inc. (NYSE:MRK) added $2.80 to $56.16 Monday after reporting that Keytruda pembrolizumab as monotherapy met the primary endpoint of improving overall survival (OS) in the Phase III KEYNOTE-042 trial as first-line treatment of non-small cell lung cancer. The move translates to an increase in the pharma's market cap of more than $7.5 billion.
The trial enrolled 1,274 patients with locally advanced or metastatic NSCLC, including both squamous and non-squamous histologies, expressing PD-L1 in at least 1% of tumor cells to receive Keytruda alone or standard of care (SOC) platinum-based chemotherapy. Based on a recommendation from an IDMC, Merck said the trial will continue to evaluate the secondary endpoint of progression-free survival (PFS). The company plans to present the data at an upcoming medical meeting and to submit the data to regulatory authorities worldwide. ...
BCIQ Company Profiles
BCIQ Target Profiles